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educing the
isk of Emergency
ypass Surgery for
ailed Percutaneous
oronary Interventions*
ohn A. Bittl, MD, FACC
cala, Florida
n this issue of the Journal, Yang et al. (1) from the Mayo
linic report the changing incidence and outcomes of
mergency coronary artery bypass surgery for failed percu-
aneous coronary interventions (PCIs). The good news is
hat the rate of emergency bypass surgery declined dramat-
cally, falling from 2.9% in the pre-stent era (1979 to 1994)
o 0.7% in the early-stent era (1995 to 1998) and showing a
urther decrease to 0.3% in the current-stent era (1999 to
003). The bad news is that the in-hospital mortality for
mergency bypass surgery remained constant and high at
0% to 14%.
See page 2004
A description of what went wrong in each case could
dentify areas for improvement. The Mayo group analyzed
heir database and found that patients sent for emergency
ypass surgery had a higher incidence of prior revascular-
zation, reduced ejection fractions, and more complex cor-
nary anatomy than those with uneventful PCIs. After the
ntroduction of stents, fewer patients with abrupt closure
nd dissections required emergency bypass surgery than in
he pre-stent era. The database analysis generated helpful
road clinical observations but could not define the root
ause of PCI failures that continued to occur after the
vailability of stents. A dutiful fellow-in-training could have
eviewed charts, interviewed the laboratory staff, and pored
hrough narratives to identify whether catastrophes such as
essel perforation, balloon non-deflation, or other types of
evice failure played a role; but the additional information
ight have been too heterogeneous for a database analysis.
Additional insights into reasons for emergency bypass
urgery in the current era have come from investigators at
he Cleveland Clinic (2). Like the Mayo Clinic group,
eshadri et al. (2) reported a dramatic 10-fold reduction in
eferrals for emergency bypass surgery between 1992 and
002 and also decried a persistent high mortality rate of
5%. These investigators found that vessel perforation or
*Editorials published in the Journal of American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or thew
merican College of Cardiology.
From the Ocala Heart Institute, Munroe Regional Medical Center, Ocala, Florida.ardiac tamponade accounted for emergency bypass surgery
n 20% of cases. Unfortunately, such events have been
ifficult to predict (3). Additional improvements have been
eeded to enhance the safety of PCI.
Platelet glycoprotein (GP) IIb/IIIa inhibitors have been
ommonly theorized as reducing the need for emergency
ypass surgery, but there is little direct proof for this
ypothesis. The Cleveland Clinic group (2) identified stent-
ng as independently associated with the decreased need for
mergency bypass surgery, whereas the use of GP IIb/IIIa
nhibitors was not. Several randomized trials of GP IIb/IIIa
nhibitors (4–7) have failed to show a significant reduction
n emergency bypass surgery, as strictly defined in the
urrent report (1) and in the guidelines for bypass surgery
8). (“Emergency” bypass surgery is performed within hours
o avoid significant morbidity and mortality, “salvage” by-
ass surgery is performed under cardiopulmonary resuscita-
ion, “urgent” bypass surgery is performed during the same
ospitalization, and “elective” bypass surgery is performed
fter hospital discharge.)
Reducing the need for emergency bypass surgery further
ight require a change in practice. Some PCI settings exist
here potent antiplatelet agents are conventionally used but
robably should be avoided. For example, during the ag-
ressive recanalization of chronic total occlusions, up to 4%
f patients have had cardiac tamponade and up to 18% have
ad vessel perforation (9). Using a reversible anticoagulant
e.g., unfractionated heparin) and avoiding clopidogrel pre-
reatment or GP IIb/IIIa inhibitors might reduce the
onsequences of “wire exit” or perforation in this setting.
The declining routine use of atherectomy, cutting balloon
therotomy, or laser angioplasty might also reduce the risk
f mechanical complications. The Mayo Clinic group (10)
eported that the use of atheroablative devices was the most
ommon cause of coronary perforation in their interven-
ional program. A meta-analysis (11) of 16 randomized
rials of atherectomy, cutting balloon atherotomy, or laser
ngioplasty versus balloon angioplasty in 9,222 patients
howed an increased risk of major adverse cardiac events at
0 days (5.1% vs. 3.3%; odds ratio [OR] 1.54, 95%
onfidence interval [CI] 1.25 to 1.89) but no reduction in
mergency bypass surgery (1.1% vs. 0.9%; OR 1.18, 95% CI
.75 to 1.78) or angiographic restenosis (38.9% vs. 37.4%;
R 1.06; 95% CI 0.97 to 1.17).
When extraordinary mechanical complications occur
uring PCI, a panoply of innovative percutaneous treat-
ents now exists to avert the need for emergency bypass
urgery. Free coronary perforations can be classified
romptly (12) and sealed with commercially available
olytetrafluoroethlyene-covered stents (13). Fractured
uidewires can be entrapped and braided within two or
hree wound guidewires and extracted from the body. Lost
tents can be neutralized or retrieved with one of at least five
ublished methods (14). Stenoses that cannot be reached
ith stent delivery systems might be approachable after the
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December 6, 2005:2010–2 Editorial Commentse of rotational atherectomy for proximal calcification. The
se of improved guide-catheter support along with “buddy
ire” (15), “buddy balloon” (16), or proximal stent-paving
ight overcome proximal tortuosity that prevents stenting
f spiral dissections. Undilatable lesions might respond to
he (selective) use of cutting balloon atherotomy (17),
otational atherectomy (18), or excimer laser angioplasty
19). No-reflow—a problem that should never be referred
or emergency bypass surgery—is reduced dramatically in
aphenous vein grafts with distal protection devices (20,21)
nd can be abrogated with pharmacologic agents such as
erapamil or adenosine. Stent closure in coronary bifurca-
ions can be almost completely eliminated by using simul-
aneous “kissing” balloons and provisional sidebranch stent-
ng (22).
The innovative methods for handling PCI misadventures
nd low rates of emergency bypass surgery might engender
he hubris that on-site surgical facilities are not necessary.
lthough direct PCI for acute myocardial infarction might
e justified in experienced centers without on-site surgery
ecause thrombolytic therapy for acute myocardial infarc-
ion is so inferior (23–25), this does not justify elective or
rgent PCI without surgical back-up. Emergency referrals
n most centers will likely be higher than at a premier
nterventional center like the Mayo Clinic. The case-fatality
ate would also be higher if transfer to a “cold” off-site
urgical team for emergency bypass surgery is made over the
hone without the possibility of on-site assessment. Such a
ogistic challenge could reverse the favorable trend in lower
n-laboratory deaths from 0.4% to 0.2% at the Mayo Clinic
rom 1979 to 2003 (1).
After all stopgap measures are exhausted and referral for
mergency bypass surgery becomes certain, the hard work
eally begins for the interventional cardiologist. The concept
f a “hand off” is a myth. Instead, the interventional
ardiologist becomes a critical member of the operating-
oom team to manage antithrombotic therapy, oversee the
xpeditious retrieval of device fragments, and hold discus-
ions with the patient’s family. The postoperative period is
arked by a high incidence of myocardial infarction, con-
estive heart failure, and complex arrhythmias (1); there-
ore, full-time cardiology care is required. Respiratory fail-
re, probably representing a component of multisystem
rgan failure, is a common cause of death after emergency
ypass surgery (1); thus, early consultation with critical-care
pecialists is recommended.
In closing, stents have reduced the need for emergency
ypass surgery for the simple reason that they are a mechan-
cal solution to a mechanical problem. Pharmacology has
rguably played an adjunctive role. The report from the
ayo Clinic (1) presents sobering statistics about persis-
ently high mortality after emergency bypass surgery for
ailed PCI. This report does not inculpate emergency bypass
urgery, which is lifesaving for the majority of those who
eed it, but has established an important benchmark fornterventional practice and should stimulate the exploration
f further enhancements of PCI technique and safety.
eprint requests and correspondence: Dr. John A. Bittl, Ocala
eart Institute, Interventional Cardiology, 13013 Highway 475,
cala, Florida 34480-8503. E-mail: jabittl@aol.com.
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